[1] WOUTERS O J, MCKEE M, LUYTEN J. Estimated research and development investment needed to bring a new medicine to market, 2009-2018 [J]. JAMA, 2020, 323(9): 844-853.
[2] DIMASI J A, GRABOWSKI H G, HANSEN R W. Innovation in the pharmaceutical industry: new estimates of R&D costs [J]. Journal of Health Economics, 2016, 47: 20-33.
[3] YASI E A, KRUYER N S, PERALTA-YAHYA P. Advances in G protein-coupled receptor high-throughput screening [J]. Current Opinion in Biotechnology, 2020, 64: 210-217.
[4] BLAY V, TOLANI B, HO S P, et al. High-throughput screening: today’s biochemical and cell-based approaches [J]. Drug Discovery Today, 2020, 25(10): 1807-1821.
[5] BLUNDELL T L. Structure-based drug design [J]. Nature, 1996, 384(6604): 23.
[6] BACILIERI M, MORO S. Ligand-based drug design methodologies in drug discovery process: an overview [J]. Current Drug Discovery Technologies, 2006, 3(3): 155-165.
[7] BIAN Y-M, HE X-B, JING Y-K, et al. Computational systems pharmacology analysis of cannabidiol: a combination of
chemogenomics-knowledgebase network analysis and integrated in silico modeling and simulation [J]. Acta Pharmacologica Sinica, 2019, 40(3): 374-386.
[8] BIAN Y, FENG Z, YANG P, et al. Integrated in silico fragment-based drug design: case study with allosteric modulators on
metabotropic glutamate receptor 5 [J]. The AAPS Journal, 2017, 19: 1235-1248.
[9] WANG J, WOLF R M, CALDWELL J W, et al. Development and testing of a general amber force fifield [J]. Journal of Computational Chemistry, 2004, 25(9): 1157-1174.
[10] GE H, BIAN Y, HE X, et al. Significantly different effects of tetrahydroberberrubine enantiomers on dopamine D1/D2 receptors revealed by experimental study and integrated in silico simulation [J]. Journal of Computer-Aided Molecular Design, 2019, 33: 447-459.
[11] WANG Z-Z, SHI X-X, HUANG G-Y, et al. Fragment-based drug discovery supports drugging ‘undruggable’ protein-protein
interactions [J]. Trends in Biochemical Sciences, 2023, 48(6): 539-552.
[12] BIAN Y, XIE X-Q. Computational fragment-based drug design: current trends, strategies, and applications [J]. The AAPS Journal, 2018, 20: 1-11.
[13] BIAN Y. Computational fragment-based discovery of allosteric modulators on metabotropic glutamate receptor 5 [D]. Pittsburgh, PA: University of Pittsburgh, 2017.
[14] SHARMA P, SHARMA S, YADAV Y, et al. Current pharmacophore based approaches for the development of new anti-Alzheimer’s agents [J]. Bioorganic & Medicinal Chemistry, 2024: 117926.
[15] ACHARYA A, YADAV M, NAGPURE M, et al. Molecular medicinal insights into scaffold hopping-based drug discovery success [J]. Drug Discovery Today, 2024, 29(1): 103845.
[16] NASSER M, YUSOF U K, SALIM N. Deep learning based methods for molecular similarity searching: a systematic review [J]. Processes, 2023, 11(5): 1340.
[17] BIAN Y, HOU G, XIE X-Q. Artificial intelligence generative chemistry design of target-specific scaffold-focused small molecule drug libraries [M]//JAGADEESH G, BALAKUMAR P, SENATORE F (eds). The Quintessence of Basic and Clinical Research and Scientifific Publishing. Singapore: Springer, 2023: 503-521.
[18] JING Y, BIAN Y, HU Z, et al. Deep learning for drug design: an artifificial intelligence paradigm for drug discovery in the big data era [J]. The AAPS Journal, 2018, 20: 1-10.
[19] BIAN Y, XIE X-Q. Generative chemistry: drug discovery with deep learning generative models [J]. Journal of Molecular Modeling, 2021, 27: 1-18.
[20] IVANENKOV Y, ZAGRIBELNYY B, MALYSHEV A, et al. The hitchhiker’s guide to deep learning driven generative chemistry [J]. ACS Medicinal Chemistry Letters, 2023, 14(7): 901-915.
[21] BIAN Y, JUN J J, CUYLER J, et al. Covalent allosteric modulation: An emerging strategy for GPCRs drug discovery [J]. European Journal of Medicinal Chemistry, 2020, 206: 112690.
[22] CHEN Y, BIAN Y, WANG J-W, et al. Effects of α-mangostin derivatives on the Alzheimer’s disease model of rats and their mechanism: A combination of experimental study and computational systems pharmacology analysis [J]. ACS Omega, 2020, 5(17): 9846-9863.
[23] KWON J J, HAJIAN B, BIAN Y, et al. Structure-function analysis of the SHOC2-MRAS-PP1C holophosphatase complex [J]. Nature, 2022, 609(7926): 408-415.
[24] SHANKAR S, PAN J, YANG P, et al. Viral DNA polymerase structures reveal mechanisms of antiviral drug resistance [J]. Cell, 2024, 187(20): 5572-5586. e15.
[25] BIAN Y, JING Y, WANG L, et al. Prediction of orthosteric and allosteric regulations on cannabinoid receptors using supervised machine learning classifiers [J]. Molecular Pharmaceutics, 2019, 16(6): 2605-2615.
[26] HOU T, BIAN Y, MCGUIRE T, et al. Integrated multi-class classification and prediction of GPCR allosteric modulators by machine learning intelligence [J]. Biomolecules, 2021, 11(6): 870.
[27] GENTILE F, YAACOUB J C, GLEAVE J, et al. Artificial intelligence–enabled virtual screening of ultra-large chemical libraries with deep docking [J]. Nature Protocols, 2022, 17(3): 672-697.
[28] BIAN Y, KWON J J, LIU C, et al. Target-driven machine learning-enabled virtual screening (TAME-VS) platform for early-stage hit identification [J]. Frontiers in Molecular Biosciences, 2023, 10: 1163536.
[29] BIAN Y. The research and development of an artifificial intelligence integrated fragment-based drug design platform for small molecule drug discovery [D]. Pittsburgh, PA: University of Pittsburgh, 2021.
[30] WANG M, WANG Z, SUN H, et al. Deep learning approaches for de novo drug design: An overview [J]. Current Opinion in Structural Biology, 2022, 72: 135-144.
[31] ABOUCHEKEIR S, VU A, MUKAIDAISI M, et al. Adversarial deep evolutionary learning for drug design [J]. Biosystems, 2022, 222: 104790.
[32] ALI F, KHALID M, ALMUHAIMEED A, et al. IP-GCN: A deep learning model for prediction of insulin using graph convolutional network for diabetes drug design [J]. Journal of Computational Science, 2024, 81: 102388.
[33] RAMESH A, RAO A S, MOUDGALYA S, et al. GAN based approach for drug design [C]// 2021 20th IEEE International Conference on Machine Learning and Applications (ICMLA). Pasadena, CA: IEEE, 2021: 825-828. DOI: 10.1109/ICMLA52953.2021.00136.
[34] GUPTA A, MÜLLER A T, HUISMAN B J, et al. Generative recurrent networks for de novo drug design [J]. Molecular Informatics, 2018, 37(1/2): 1700111.
[35] ALAKHDAR A, POCZOS B, WASHBURN N. Diffusion models in de novo drug design [J]. Journal of Chemical Information and Modeling, 2024, 64(19): 7238-7256.
[36] GOODFELLOW I, POUGET-ABADIE J, MIRZA M, et al. Generative adversarial networks [J]. Communications of the ACM,
2020, 63(11): 139-144.
[37] BIAN Y, WANG J, JUN J J, et al. Deep convolutional generative adversarial network (dcGAN) models for screening and design of small molecules targeting cannabinoid receptors [J]. Molecular Pharmaceutics, 2019, 16(11): 4451-4460.
[38] BIAN Y, XIE X-Q. Artificial intelligent deep learning molecular generative modeling of scaffold-focused and cannabinoid CB2 target-specific small-molecule sublibraries [J]. Cells, 2022, 11(5): 915
